EMPA-REG Kidney Visual Abstract While empagliflozin was the first out with a CVOT, canagliflozin was the first to complete a kidney-focused flozin trial, CREDENCE, which convincingly answered any doubts from the earlier trials
Life 14(4):479 Alquisiras-Burgos I et al (2024) Nose-to brain delivery of resveratrol, a non-invasive method for the treatment of cerebral ischemia
Whether you are dealing with Mounjaro face, tirzepatide face, or semaglutide face, the mechanism is the same
Delayed digestion of food gives a feeling of satiety, but it can also cause these gastrointestinal side effects
No evidence of severe cardiovascular, hepatic, or endocrine adverse effects has been observed within standard research dosing ranges in available data
Without clear expertise signals, a proper content structure, and real local relevance, that content just sits on page five and does nothing